A Phase 3 interventional study of Selexipag and Placebo in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 182 sites in 39 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one has the largest enrollment, is the only one that started in 2009, is one of 6 in phase 3, and was the 1st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,156 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one has the largest enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2009, is one of 31 in phase 3, and was the 23rd registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing selexipag in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
Drug: Selexipag
Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
Drug: Placebo
Selexipag 200 µg tablets
Also known as: ACT-293987
Placebo tablets matching selexipag
Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake
Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points). Morbidity event was defined as any of the following events confirmed by the Critical Event committee: * Hospitalization for worsening of pulmonary arterial hypertension (PAH), * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy, * Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH, * Disease progression which was defined by a decrease in 6-minute walk distance from baseline (\>=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline. Note: The number of patients at risk decreased over time but this cannot be captured below
Time frame: Up to 7 days after end of double-blind treatment (maximum: 4.3 years)
Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough
The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.
Time frame: Week 26
Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)
Time frame: Week 26
A total of 1351 patients were screened from 181 sites in 39 countries worldwide. Of these, 1156 were randomized
| Milestone | SELEXIPAG | PLACEBO |
|---|---|---|
| Started | 574 | 582 |
| Completed | 289 | 252 |
| Not completed | 285 | 330 |
| Withdrew: Morbidity or mortality primary endpoint | 155 | 242 |
| Withdrew: Adverse event | 78 | 42 |
| Withdrew: Withdrawal by subject | 43 | 37 |
| Withdrew: Administrative reason | 7 | 6 |
| Withdrew: Lost to follow-up | 2 | 3 |
Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points). Morbidity event was defined as any of the following events confirmed by the Critical Event committee: * Hospitalization for worsening of pulmonary arterial hypertension (PAH), * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy, * Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH, * Disease progression which was defined by a decrease in 6-minute walk distance from baseline (\>=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline. Note: The number of patients at risk decreased over time but this cannot be captured below
| Percentage of patients free of events | Selexipag | Placebo |
|---|---|---|
| KM estimate at Month 6 | 91.2 (88.5 to 93.4) | 81.7 (78.2 to 84.7) |
| KM estimate at Month 12 | 83.1 (79.5 to 86.1) | 70.6 (66.6 to 74.3) |
| KM estimate at Month 18 | 75.5 (71.2 to 79.2) | 61.3 (56.8 to 65.5) |
| KM estimate at Month 24 | 67.9 (63.0 to 72.4) | 53.9 (49.0 to 58.5) |
| KM estimate at Month 30 | 61.9 (56.3 to 66.9) | 49.3 (44.2 to 54.3) |
| KM estimate at Month 36 | 58.2 (51.7 to 64.1) | 41.7 (35.2 to 48.0) |
The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.
| Meters | Selexipag | Placebo |
|---|---|---|
| 6MWD at baseline - Overall | 376 (90 to 482) | 369 (50 to 515) |
| 6MWD at Week 26- Overall | 370 (0 to 617) | 346 (0 to 650) |
| 6MWD Change from baseline at Week 26 | 4 (-448 to 260) | -9 (-438 to 262) |
| Percentage of patients | Selexipag | Placebo |
|---|---|---|
| Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC) | 77.8 | 74.9 |
Collected over From baseline up to up to 7 days after end of treatment (EOT). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag | — | 252/575 (43.8%) | 544/575 (94.6%) |
| Placebo | — | 272/577 (47.1%) | 486/577 (84.2%) |
| Event | Selexipag | Placebo |
|---|---|---|
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 83/575 | 127/577 |
| RIGHT VENTRICULAR FAILURECardiac disorders | 34/575 | 41/577 |
| PNEUMONIAInfections and infestations | 17/575 | 25/577 |
| SYNCOPENervous system disorders | 10/575 | 20/577 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 17/575 | 13/577 |
| ATRIAL FIBRILLATIONCardiac disorders | 7/575 | 4/577 |
| BRONCHITISInfections and infestations | 6/575 | 4/577 |
| CHEST PAINGeneral disorders | 6/575 | 6/577 |
| RENAL FAILURE ACUTERenal and urinary disorders | 6/575 | 6/577 |
| FALLInjury, poisoning and procedural complications | 3/575 | 6/577 |
| Event | Selexipag | Placebo |
|---|---|---|
| HEADACHENervous system disorders | 374/575 | 189/577 |
| DIARRHOEAGastrointestinal disorders | 242/575 | 109/577 |
| NAUSEAGastrointestinal disorders | 192/575 | 107/577 |
| PAIN IN JAWMusculoskeletal and connective tissue disorders | 148/575 | 36/577 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 79/575 | 110/577 |
| VOMITINGGastrointestinal disorders | 103/575 | 48/577 |
| OEDEMA PERIPHERALGeneral disorders | 77/575 | 100/577 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 95/575 | 46/577 |
| MYALGIAMusculoskeletal and connective tissue disorders | 90/575 | 34/577 |
| DIZZINESSNervous system disorders | 85/575 | 85/577 |
| Age, Continuous(Years) | Selexipag | Placebo | Total |
|---|---|---|---|
| Mean | 48.2 ± 15.19 | 47.9 ± 15.55 | 48.1 ± 15.37 |
| Sex: Female, Male(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| Female | 457 | 466 | 923 |
| Male | 117 | 116 | 233 |
| Race/Ethnicity, Customized(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| Caucasion / White | 376 | 375 | 751 |
| Asian | 125 | 120 | 245 |
| Hispanic | 51 | 63 | 114 |
| Black | 13 | 14 | 27 |
| Other | 9 | 10 | 19 |
| Region of Enrollment(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| Western Europe & Australia | 161 | 160 | 321 |
| Eastern Europe | 149 | 155 | 304 |
| Asia | 115 | 113 | 228 |
| North America | 95 | 98 | 193 |
| Latin America | 54 | 56 | 110 |
| PAH etiology(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| Idiopathic | 312 | 337 | 649 |
| Heritable | 13 | 13 | 26 |
| Associated with connective tissue disease | 167 | 167 | 334 |
| Assoc. with corrected (>=12Mo) congenital shunts | 60 | 50 | 110 |
| Associated with drug or toxin exposure | 17 | 10 | 27 |
| Associated with HIV infection | 5 | 5 | 10 |
| Modified NYHA/WHO Functional class (FC)(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| FC I | 4 | 5 | 9 |
| FC II | 274 | 255 | 529 |
| FC III | 293 | 314 | 607 |
| FC IV | 3 | 8 | 11 |
| PAH medications at baseline(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| None | 112 | 124 | 236 |
| Endothelin Receptor Agonists (ERA) | 94 | 76 | 170 |
| Phosphodiesterase type 5 inhibitors (PDE5-I) | 189 | 185 | 374 |
| ERA and PDE5I in combination | 179 | 197 | 376 |
| Time since PAH diagnosis(Years) | Selexipag | Placebo | Total |
|---|---|---|---|
| Median | 0.9 (0.0 to 37.3) | 1.1 (0.0 to 38.9) | 1.0 (0.0 to 38.9) |
1 further baseline measures are reported on the registry.
Showing the first 100 of 182 sites across 39 countries. Choose a country and city above to see the rest.
Ran from Dec 2009 to primary completion in Apr 2014, 52 months.
Results were first posted in Mar 2016, 1 year 11 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 52 months is close to that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag
Pulmonary Arterial Hypertension →